麦利查咪 | 26921-72-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 麦利查咪
• 英文名称: Melizame
• 英文别名: 3-(2H-tetrazol-5-yloxy)phenol
• CAS: 26921-72-2
• 化学式: C₇H₆N₄O₂
• mdl: MFCD00868125
• 分子量: 178.15
• InChiKey: DZHBTQHPZSGDOR-UHFFFAOYSA-N

物化性质

• 沸点：
  419.2±47.0 °C(Predicted)
• 密度：
  1.529±0.06 g/cm3(Predicted)
• 物理描述：
  Solid
• 熔点：
  141-143°C

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  83.9
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• [EN] CARBONATE PRODRUGS AND METHODS OF USING THE SAME<br/>[FR] PROMÉDICAMENTS CARBONATÉS ET LEURS MÉTHODES D'UTILISATION
  申请人：NEUROGESX INC

  公开号：WO2009143297A1

  公开（公告）日：2009-11-26

  The present invention provides carbonate prodrugs which comprise a carbonic phosphoric anhydride prodrug moiety attached to the hydroxyl or carboxyl group of a parent drug moiety. The prodrugs may provide improved physicochemical properties over the parent drug. Also provided are methods of treating a disease or condition that is responsive to the parent drug using the carbonate prodrugs, as well as kits and unit dosages.

  本发明提供了碳酸盐前药，其包括连接到母药基团的羟基或羧基上的碳酸磷酸酐前药基团。这些前药可能比母药具有改进的物理化学性质。还提供了使用碳酸盐前药治疗对母药具有响应的疾病或症状的方法，以及配套工具和单剂量。
• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• CARBONATE PRODRUGS AND METHODS OF USING THE SAME
  申请人：Muhammad Naweed

  公开号：US20110212927A1

  公开（公告）日：2011-09-01

  The present invention provides carbonate prodrugs which comprise a carbonic phosphoric anhydride prodrug moiety attached to the hydroxyl or carboxyl group of a parent drug moiety. The prodrugs may provide improved physicochemical properties over the parent drug. Also provided are methods of treating a disease or condition that is responsive to the parent drug using the carbonate prodrugs, as well as kits and unit dosages.

  本发明提供了碳酸盐前药，其包括一个碳酸磷酸酐前药基团，附着在母药基团的羟基或羧基上。这些前药可能比母药具有更好的物理化学性质。还提供了使用碳酸盐前药治疗对母药有反应的疾病或病症的方法，以及工具包和单元剂量。
• Sweetened oral compositions, preferably toothpastes or mouthwash compositions
  申请人：THE PROCTER & GAMBLE COMPANY

  公开号：EP0008480A1

  公开（公告）日：1980-03-05

  Oral compositions, preferably toothpastes or mouthwash compositions, which contain as a sweetening agent with desirable sweetness 6-methyl-3,4- dihydro- 1,2,3-oxathiazin-4-one -2,2-dioxide of the formula or an alkali metal or alkaline earth salt thereof in an amount of from about 0,05 % to about 0,80 %.

  口服组合物，最好是牙膏或漱口水组合物，其中含有具有理想甜度的 6-甲基-3,4-二氢-1,2,3-氧硫杂嗪-4-酮-2,2-二氧化物（式中）或其碱金属盐或碱土盐，含量约为 0.05 % 至约 0.80 %。
• Carbonate prodrugs and methods of using the same
  申请人：Acorda Therapeutics, Inc.

  公开号：US10377779B2

  公开（公告）日：2019-08-13

  The present invention provides carbonate prodrugs which comprise a carbonic phosphoric anhydride prodrug moiety attached to the hydroxyl or carboxyl group of a parent drug moiety. The prodrugs may provide improved physicochemical properties over the parent drug. Also provided are methods of treating a disease or condition that is responsive to the parent drug using the carbonate prodrugs, as well as kits and unit dosages.

  本发明提供的碳酸盐原药由碳酸磷酸酐原药分子组成，该分子与母药分子的羟基或羧基相连。与母药相比，原药可提供更好的理化性质。此外，还提供了使用碳酸盐原药治疗对母药有反应的疾病或病症的方法，以及试剂盒和单位剂量。